Core Viewpoint - Haizheng Pharmaceutical announced a significant impairment loss totaling 64.44 million yuan, which will reduce the company's profit for the third quarter of 2025 by the same amount [1] Financial Performance - The company recognized a credit impairment loss of 1.4013 million yuan and an asset impairment loss of 63.0436 million yuan, leading to a total impairment of 64.4449 million yuan [1] - The impairment data is unaudited, and the final impact on the company's financials will be confirmed after the annual audit by the accounting firm [1] Revenue Composition - For the year 2024, Haizheng Pharmaceutical's revenue composition is as follows: - Pharmaceutical production: 58.46% - Drug sales: 39.29% - Other industries: 1.94% - Other businesses: 0.23% - CMO/CDMO/CRO business: 0.08% [1] Market Capitalization - As of the report, Haizheng Pharmaceutical has a market capitalization of 12.6 billion yuan [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-62 号 一、本次计提资产减值准备情况概述 公司根据依照《企业会计准则第 8 号——资产减值》《企业会计准则第 22 号 ——金融工具确认和计量》等相关规定以及公司的实际业务情况，对公司 2025 年第三季度合并范围内相关资产进行减值测试，根据测试结果，公司部分资产存 在减值的情形，计提各项减值损失 6,444.49 万元，具体如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开 第十届董事会第八次会议，审议通过了《关于计提资产减值准备的议案》，为了 更加客观、公正地反映公司财务状况和资产价值，根据《企业会计准则》等相关 规定，结合企业实际经营情况和资产现状，本着谨慎性原则，对 2025 年第三季 度各项资产进行了减值迹象的识别和测试，并根据测试结果对其中存在减值迹象 的资产相应计提资产减值准备，现将具体情况公告如下： 备注：负数为损失转回，正数为损失增加。 本次计提资产减 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临2025-63号 浙江海正药业股份有限公司 关于召开2025年第二次临时股东会的通知 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (四)现场会议召开的日期、时间和地点 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 12 日 至2025 年 11 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 召开的日期时间：2025 年 11 月 12 日 13 点 00 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） 股东会召开日期：2025年11月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二)股东会召 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Haizheng Pharmaceutical for the third quarter of 2025, indicating a slight increase in revenue but a decline in net profit and earnings per share [1] Group 2 - Haizheng Pharmaceutical reported revenue of approximately 7.923 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 0.61% [1] - The net profit attributable to shareholders of the listed company was approximately 461 million yuan, showing a year-on-year decrease of 10.55% [1] - The basic earnings per share were 0.4 yuan, reflecting a year-on-year decrease of 9.09% [1] - As of the report date, Haizheng Pharmaceutical's market capitalization stood at 12.6 billion yuan [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、2025 年第三季度报告； 同意 9 票，反对 0 票，弃权 0 票。 浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）第十届 董事会第八次会议于 2025 年 10 月 27 日上午以通讯方式召开，应参加本次会议 董事 9 人，亲自参加会议董事 9 人。本次会议的召开程序符合《公司法》和《公 司章程》的规定，会议合法有效。本次会议由公司董事长肖卫红先生主持，经审 议，与会董事以通讯表决方式通过了如下决议： 一、关于计提资产减值准备的议案； 同意 9 票，反对 0 票，弃权 0 票。 详见《浙江海正药业股份有限公司关于计提资产减值准备的公告》，已登载 于 2025 年 10 月 28 日的《中国证券报》《上海证券报》《证券时报》和上海证券 交易所网站（www.sse.com.cn）上。 证券代码：600267 证券简称：海正药业 公告编号：临 2025-61 号 浙江海正药业股份有限公司 第十届董事会第八次会议决议公告 四、关于确认公司第十届董事会审计委员会成员和召 ...

Financial Performance - The company's revenue for the third quarter reached ¥2,672,459,633.39, an increase of 1.57% compared to the same period last year[4] - Total profit for the quarter was ¥215,434,956.96, representing a significant increase of 79.59% year-over-year[4] - Net profit attributable to shareholders was ¥161,858,607.96, up 102.14% compared to the same quarter last year[4] - The net profit excluding non-recurring gains and losses for the quarter was ¥169,287,578.00, reflecting a 96.13% increase year-over-year, driven by growth in sales of formulations and animal drugs[4][9] - Basic earnings per share for the quarter was ¥0.14, a 100% increase compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥7,922,794,186.82, a slight increase from ¥7,874,540,640.41 in the same period of 2024, representing a growth of approximately 0.61%[23] - Net profit for the first three quarters of 2025 was ¥468,057,810.10, down from ¥510,285,014.19 in 2024, reflecting a decline of approximately 8.27%[24] - Total revenue for the first three quarters of 2025 reached ¥8,563,322,286.31, an increase from ¥8,365,256,571.78 in the same period of 2024, reflecting a growth of approximately 2.4%[27] - Basic and diluted earnings per share for the current period were both ¥0.40, down from ¥0.44 in the previous year[25] - The total comprehensive income attributable to the parent company for the first three quarters of 2025 was ¥459,603,789.62, a decrease from ¥514,800,610.01 in 2024[25] Assets and Liabilities - Total assets at the end of the quarter were ¥15,317,639,964.13, a decrease of 4.10% from the end of the previous year[5] - The company's total assets decreased to ¥15,317,639,964.13 from ¥15,972,478,068.00, a decline of approximately 4.09%[21] - Total liabilities decreased to ¥6,562,369,900.01 from ¥7,393,464,632.58, representing a reduction of about 11.24%[20] - The equity attributable to shareholders increased to ¥8,510,481,174.57, up 2.03% from the end of the previous year[5] - The company's equity attributable to shareholders increased to ¥8,510,481,174.57 from ¥8,341,353,163.16, showing an increase of approximately 2.03%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,644,663,551.07, an increase of 12.99%[4] - Net cash flow from operating activities for the first three quarters of 2025 was ¥1,644,663,551.07, compared to ¥1,455,579,860.77 in 2024, indicating an increase of about 12.9%[28] - The company reported a net cash outflow from investing activities of ¥198,673,150.61 in 2025, worsening from a net outflow of ¥120,299,452.25 in 2024[28] - Cash and cash equivalents at the end of Q3 2025 amounted to ¥1,392,479,467.78, up from ¥1,193,265,560.31 at the end of Q3 2024[29] - The company's cash and cash equivalents decreased to ¥51,258,502.22 from ¥69,771,512.72, a decline of approximately 26.66%[21] - As of September 30, 2025, the company's cash and cash equivalents amounted to RMB 1,516,606,462.28, an increase from RMB 1,497,647,788.41 at the end of 2024[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 54,361[11] - Zhejiang Haizheng Group Co., Ltd. holds 320,783,590 shares, accounting for 26.76% of the total shares[11] - The company has repurchased 35,711,300 shares, representing 2.98% of the total share capital, for future employee stock ownership plans[12] - The top ten shareholders include state-owned enterprises, with Zhejiang Haizheng Group being the largest shareholder[11] - The company has not identified any related party transactions among its shareholders[12] Expenses and Investments - Research and development expenses increased to ¥372,154,095.37 from ¥262,633,894.43, indicating a rise of about 41.73%[23] - The company reported a significant increase in sales expenses, which rose to ¥1,609,805,985.09 from ¥1,583,085,460.85, an increase of about 1.69%[23] - The company experienced a loss in investment income of ¥34,534,648.03 compared to a gain of ¥181,056,163.81 in the previous year[24] - The company plans to invest RMB 50 million in Nanjing Jisheng Aoma Biopharmaceutical Co., Ltd., holding 10.9890% of its shares[14] - The company has completed the transfer of shares to Growth River Investment Limited and Empire Gateway Investment Limited as part of a settlement agreement[13] Non-Recurring Items - Non-recurring gains and losses for the quarter totaled -¥7,428,970.04, with significant impacts from various adjustments and losses[8] - The company experienced a decrease in tax refunds received, totaling ¥13,156,921.23 in 2025 compared to ¥51,151,542.76 in 2024[27] - Cash inflow from financing activities in 2025 was ¥1,431,330,849.25, significantly lower than ¥3,452,000,000.00 in 2024[28] - The company paid out ¥323,720,682.87 in dividends and interest in 2025, compared to ¥112,231,571.14 in 2024, indicating a substantial increase in cash outflows[28] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥231,228.83 in 2025, compared to a positive impact of ¥2,597,714.07 in 2024[28]

海正药业10月27日公告，2025年第三季度实现营业收入26.72亿元，同比增长1.57%；归属于上市公司股 东的净利润1.62亿元，同比增长102.14%；基本每股收益0.14元。前三季度实现营业收入79.23亿元，同 比增长0.61%；归属于上市公司股东的净利润4.61亿元，同比下降10.55%。 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-60 号 会议召开时间：2025 年 11 月 3 日（星期一）15:00-16:00 会议召开地点：上海证券交易所上证路演中心 浙江海正药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 27 日（星期一）至 10 月 31 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过浙江海正药业股份有 限公司（以下简称"公司"）证券管理部邮箱 stock600267@hisunpharm.com 进行 提问。公司将在信息披露允许的范围内，于说明会上对投资者普遍关注的问题进 行回答。 公司将于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has achieved a significant breakthrough in its internationalization strategy with the removal of the GMP non-compliance statement for its Taizhou factory by the EU, marking a key milestone in the company's internationalization 2.0 strategy [1][2] Group 1: Internationalization Strategy - The removal of the EU ban is crucial for Haizheng Pharmaceutical to consolidate its market position in the EU and rebuild international customer relationships [1] - The company is advancing a "global market integration" strategy, focusing on key regions such as Brazil, the Middle East and North Africa, and the CIS and Eastern Europe, while preparing for markets in Japan and Southeast Asia [1][2] - The comprehensive recovery of the EU market reduces the company's reliance on a single market and fosters deep strategic collaboration with markets in the US and Brazil, creating a new pattern of multi-regional and multi-sector collaboration [1][2] Group 2: Quality Management and Compliance - The EU's GMP certification is known as the "gold standard" in the pharmaceutical industry, and the initial non-compliance was due to deficiencies in handling hazardous materials and cross-contamination risks [2] - The company undertook a comprehensive quality improvement initiative, implementing a phased strategy to optimize various aspects of production, which led to the EU's partial withdrawal of the non-compliance statement [2][3] - The company's cGMP management system received high praise from the FDA and EDQM, indicating that it has reached an international first-class level [3] Group 3: Future Prospects and Competitive Edge - The lifting of the ban is expected to enhance the company's image, facilitate market access, and improve customer recognition, which will aid in promoting products internationally [3] - The company aims to optimize its product structure, focus on high-value and high-quality products, and expand market share, thereby enhancing profitability and core competitiveness in the global pharmaceutical supply chain [3][4] - The internationalization development reflects a broader transformation of the Chinese pharmaceutical industry from "manufacturing" to "intelligent manufacturing" and "quality manufacturing," showcasing the company's resilience in maintaining high-quality standards [5]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has achieved a significant breakthrough in its internationalization strategy with the removal of the GMP non-compliance statement for its Taizhou factory by the EU, marking a key milestone in the company's internationalization 2.0 strategy [1] Group 1: Internationalization Strategy - The removal of the GMP non-compliance statement is crucial for consolidating the company's position in the EU market and rebuilding international customer relationships [1] - The company is advancing a "global market integration" strategy, focusing on key regions such as Brazil, the Middle East and North Africa, and the Commonwealth of Independent States and Eastern Europe, while also preparing for markets in Japan and Southeast Asia [1] - The comprehensive recovery of the EU market reduces the company's reliance on a single market and fosters deep strategic collaboration with markets like the US and Brazil, creating a new pattern of multi-regional and multi-sector collaboration [1] Group 2: Quality Improvement Efforts - The EU's GMP certification is known as the "gold standard" in the pharmaceutical industry, and the non-compliance statement issued in July 2019 highlighted deficiencies in handling hazardous materials and cross-contamination risks [2] - In response, the company initiated a comprehensive quality improvement campaign, implementing a phased strategy that prioritized workshops with better foundational conditions for systematic optimization across various aspects [2] - The company's efforts were recognized by the EU, leading to a partial withdrawal of the GMP non-compliance statement in April 2021 after a remote audit [2] Group 3: Regulatory Recognition - The company's significant investments in quality management have been acknowledged by the FDA and EDQM during inspections, with the cGMP management system receiving high praise for reaching international first-class standards [3] - Following positive inspection results, the company successfully requested the withdrawal of the non-compliance statement related to the production of cytotoxic and harmful active pharmaceutical ingredients at the Taizhou factory [3]